<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618081</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-TCL-003</org_study_id>
    <secondary_id>U1111-1260-3127</secondary_id>
    <nct_id>NCT04618081</nct_id>
  </id_info>
  <brief_title>Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)</brief_title>
  <official_title>Revlimid® Capsules General Drug Use-results Survey (Relapsed or Refractory Follicular Lymphoma and Marginal Zone Lymphoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To ascertain the safety of Revlimid® Capsules 2.5 mg or 5 mg under the actual use conditions&#xD;
      in patients who received R2 combination therapy with the drug and rituximab for the first&#xD;
      time for relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).&#xD;
&#xD;
      In particular, this surveillance will collect only information of occurrence state and&#xD;
      treatment methods on bone marrow depression (neutropenia), which is specified as a safety&#xD;
      specification, as well as on tumor flare, for which attention should be called.&#xD;
&#xD;
        1. Planned registration period 1.5 years&#xD;
&#xD;
        2. Planned surveillance period 3 years from the start of this survey&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Number of participants with adverse events</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Lymphoma Nonhodgkin</condition>
  <arm_group>
    <arm_group_label>Participants with FL or MZL</arm_group_label>
    <description>Patients who have been diagnosed with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who receive R2 combination therapy with revlimid and rituximab for the first time.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This survey will be conducted in patients who have been diagnosed with follicular lymphoma&#xD;
        (FL) or marginal zone lymphoma (MZL) who receive R2 combination therapy with the drug and&#xD;
        rituximab for the first time.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  N/A&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinshu Cho</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shigeru Minohara, Study Manager</last_name>
    <phone>+81-3-5224-0660</phone>
    <email>Shigeru.Minohara@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Kumazawa, Study Manager</last_name>
    <phone>+81-3-5224-0548</phone>
    <email>Jun.Kumazawa@bms.com</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 31, 2020</study_first_submitted>
  <study_first_submitted_qc>October 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>October 31, 2020</last_update_submitted>
  <last_update_submitted_qc>October 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Nonhodgkin</keyword>
  <keyword>low-grade</keyword>
  <keyword>B-cell</keyword>
  <keyword>Follicular</keyword>
  <keyword>Marginal zone</keyword>
  <keyword>Safety</keyword>
  <keyword>Revlimid</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Actual use conditions</keyword>
  <keyword>R2 combination therapy</keyword>
  <keyword>Bone marrow depression</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Tumor flare</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:&#xD;
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

